Currently browsing tag

bengaluru

FDA staff questions Clovis drug’s efficacy over current treatments

(Reuters) – Staff reviewers from the U.S. Food and Drug Administration on Friday questioned if Clovis Oncology Inc’s lung cancer drug was more effective than available treatments. The reviewers also recommended including a black box warning, the FDA’s strictest warning, in the drug’s label. (http://1.usa.gov/1WhpSFa) Rociletinib, which is very similar to an AstraZeneca Plc drug already on the market, targets patients whose disease has worsened after treatment with other therapies. (Reporting by Amrutha Penumudi and Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)

PSivida Corp says experimental eye drug meets study goal

(Reuters) – Drugmaker pSivida Corp said its experimental eye drug prevented inflammation in the back of patients’ eyes in a late-stage study. The drugmaker said only 18.4 percent of the patients given the treatment Medidur had the condition, posterior uveitis, return, compared with 78.6 percent patients who were given placebo. The company’s shares were up 32.4 percent at $4.90 in premarket trading on Tuesday. (Reporting by Vidya L Nathan in Bengaluru; Editing by Shounak Dasgupta)

Zafgen says patient dies in obesity drug trial

(Reuters) – Drug developer Zafgen Inc said a patient died from a blockage in an artery in the lung in a late-stage study of its experimental obesity drug. The company said it is discussing with the U.S. Food and Drug Administration on the next steps for the drug, beloranib. (Reporting by Vidya L Nathan in Bengaluru; Editing by Saumyadeb Chakrabarty)

Lilly’s psoriatic arthritis drug succeeds in late-stage study

(Reuters) – Eli Lilly and Co said its experimental drug, ixekizumab, was more effective than a placebo in patients with active psoriatic arthritis, in a late-stage trial. Psoriatic arthritis is a progressive and chronic disease that can cause swelling, stiffness and pain in and around joints. (Reporting by Natalie Grover in Bengaluru; Editing by Savio D’Souza)